HOTH — Hoth Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $18.56m
- $9.55m
- 32
- 25
- 58
- 31
Annual income statement for Hoth Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 7.3 | 14.1 | 11.1 | 7.69 | 8.22 |
| Operating Profit | -7.3 | -14.1 | -11.1 | -7.69 | -8.22 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -7.2 | -14.3 | -11.4 | -7.85 | -8.19 |
| Net Income After Taxes | -7.2 | -14.3 | -11.4 | -7.85 | -8.19 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -7.2 | -14.3 | -11.4 | -7.85 | -8.19 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -7.2 | -14.3 | -11.4 | -7.85 | -8.19 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -14.6 | -16 | -9.5 | -2.3 | -1.28 |